| |
|
|
|
|
| Slide Lecture Programs |
| 2004 Core Curriculum |
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section I: Atrial fibrillation, anticoagulation, and stroke prevention |
April 16, 2004
|
| E: |
Emerging new options
Profile of direct thrombin inhibition
Slide 57 |
|
|
Download PowerPoint
|
SPORTIF V: Incidence of hemorrhage
- Intracranial hemorrhage occurred in 0.06% of each arm.1
- Major bleeding (defined as either (1) associated with a decrease in hemoglobin >2 g/dL, (2) necessitating transfusion of >2 units, or (3) involving a critical site such as intracranial) occurred in 2.4% and 3.1% of ximelagatran and warfarin patients, respectively, a nonsignificant difference.
- Combined major or minor bleeding occurred significantly less often in ximelagatran patients: 37% and 47%, respectively (P < 0.0001).
1Halperin JL. Stroke prevention using the direct oral thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: SPORTIF V. Presented at AHA Scientific Sessions 2003; Nov 11, 2003; Orlando, Fla.
|
|
|
Resources
